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The three papers discussed below explore some aspects of 
the economic burden of MS and Huntington’s disease (HD). 
In the first paper, the authors update economic data on the 
burden of MS as part of a Europe-wide study. The second 
paper looks at the cost of a clinical relapse in MS, whilst the 
third paper estimates the overall costs of HD.
New insights into the burden and costs of multiple 
sclerosis in Europe: results for the United 
Kingdom
This study aimed to update estimated costs of all heath care 
and other resource utilisation related to MS. Data was col-
lected retrospectively using standardised questionnaires as 
part of a cross-sectional retrospective study in 16 countries, 
collecting data on resource consumption, work capacity, 
health related quality of life and prevalent symptoms. Results 
were reported according to disability groupings measured 
by Expanded Disability Scale Status (EDSS 0.0–3.0 mild; 
EDSS 4.0–6.5 moderate; EDSS 7.0–9.0 severe).
Participants (n = 5928) were contacted by the national 
MS society and data analysed from a response rate that only 
reached 13%. Mean age of respondents was 56.7 years. 
Seventy-two per cent were below retirement age of which 
36% were employed. Seventy-three per cent reported fatigue 
as the most bothersome symptom, with 22% reporting sick 
leave in the past 3 months, mainly related to relapse. Rates 
of employment fell rapidly with increasing disease severity, 
and of those unemployed patients, 57% reported MS as the 
main reason.
Unsurprisingly the total annual cost of disease per patient 
increased with disease severity. In mild disease health care 
costs dominated (overall mean cost: £11,400), whereas 
in more severe disease, production loss, informal care, 
Introduction
The overall burden of neurological disease on society is 
considerable and complex with individual effects on social 
functions, employment and health care provision as well 
as secondary effects on family members and carers. Whilst 
a number of novel interventions offer great promise to 
patients, it is evident that there is a finite limit to resources 
available to health services for the introduction of new thera-
pies. As a result, there is a growing focus on data that can 
contribute to the measurement of overall societal value of 
potential interventions.
Together with other metrics, economic data can be used 
to compare effects of new treatments on overall burden dis-
ease. These data can then contribute to statistical models that 
allow estimations of long-term treatment efficacy and qual-
ity-adjusted life years (QALYs). In countries that employ 
cost-utility analysis for health technology assessment, these 
models have a fundamental influence on decisions regarding 
drug availability and reimbursement. More recently, eco-
nomic data have been particularly significant in multiple 
sclerosis (MS) as new disease-modifying therapies (DMTs) 
have become available. However, these data are equally 
relevant for other neurological diseases currently lacking 
effective treatment options, on which significant research 
and development resources are now focused.
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investments and community services dominated (overall 
mean cost: £36,500). Informal care costs also rose from 
£585 to £11,337 in mild to severe disease. Mean cost of a 
relapse was estimated at £792 and all resource use increased 
during relapse, particularly inpatient and informal care. The 
authors concluded that the study data may be used to aid 
future design of health care provision and policy changes.
Comment. This broad ranging retrospective study investi-
gated complex direct and indirect costs of health and exposes 
the complexities of understanding a number of interrelated 
factors. The respondent rate was very low despite two 
reminders, raising questions of how representative the data 
may be. In addition the study clearly has limitations in wider 
applicability since it focuses on a single health care service 
in the UK. However, these data usefully add to a wider per-
spective of a chronic and unpredictable neurological disease.
Thompson A et al. (2017) Mult Scler J 23(25) 204–216.
Multiple sclerosis: relapses, resource use, and costs
Approximately 85% of patients with MS experience relapse 
as a characteristic clinical feature of their disease from onset. 
The effect of MS relapse and subsequent use of resources 
is highly variable and commonly depends on lesion site, 
duration of associated disability and other patient specific 
external factors. In this study, the authors aim to describe 
the range of health and social care resource use and costs 
according to the frequency, severity and duration of relapse 
to provide an estimate for cost of MS relapse.
Data were collected prospectively over 8 years from 
1441 patients in the South West of England via standard-
ised questionnaire with 11,800 questionnaires available for 
analysis. Patients already enrolled in an on-going longitudi-
nal study addressing patient reported outcomes, were asked 
to retrospectively report details of up to four relapses over 
a 6-month period. Alternatively if the questionnaire was 
applied at the point of recruitment a 12-month period was 
considered. Data were collected for use of health and social 
care resources in the same period. Frequency, severity and 
duration of relapses were also recorded, along with treat-
ment interventions and inpatient admissions.
Fifty-four per cent of patients had experienced a relapse 
during the reporting period, 30.9% reported no relapse and 
14.9% were unsure. The main differences between resource 
costs in those that reported relapse versus those that did not, 
included use of a psychologist, GP, neurologist, MS special-
ist nurse or pain management service. Total mean cost in 
those that reported at least one relapse was £519, compared 
to £229 for patients who reported no relapse. Cost of relapse 
strongly correlated with relapse duration, with the greatest 
cost of relapse related to admission to hospital. However, an 
increasing number of relapses did not continuously increase 
resource use.
Comment. The authors have identified an important gap 
in the analysis of resource use in MS that has rarely been 
studied in detail. These data can be used to improve the 
understanding of cost information relating to relapses, but 
ultimately will have greatest value when studies such as this 
are standardised and applied over a number of countries and 
health care systems. Limitations once again revolve around 
the retrospective nature of the study and the self-reporting 
of relapse and disability, although the population seem 
representative.
Hawton AJ, Green C (2016) Eur J Health Econ 
17:875–884.
The societal cost of Huntington’s disease: are we 
underestimating the burden?
The worldwide prevalence of HD has been estimated at 5.7 
per 100,000 with rates of 12 per 100,000 in northern Europe. 
Despite the considerable effect of the disease both on those 
affected as well as their families, there remains few data on 
the use of health and social care resources.
Data for UK patients were obtained from the European 
Huntington’s Disease Network (EHDN) REGISTRY, a lon-
gitudinal observational study which contains data on demo-
graphics, medical history and longitudinal data including a 
Client Service Receipt Inventory which contains information 
on hospital and residential services, primary and commu-
nity care, diagnostic tests, informal care as well as aids and 
adaptations to the home. Patients were categorised by total 
functional capacity (TFC) score: stage I (the earliest stage) 
11–13; stage II 7–10; stage III 3–6; stage IV 1–2; and stage 
V 0. Cost data were collected for service contact, medica-
tion, informal care, investigations and adaptations/aids. Data 
were available for 131 individuals, but did not include any 
stage V patients.
The largest increase in cost was observed in mean annual 
cost of informal care from stage III to IV (around £40,000). 
Mean annual cost of hospital/residential care also rose from 
£99.40 to £12,566 from stage I to stage IV. Mean annual 
costs per person in stage I were £2250 and rose to £89,760 
in stage IV. Overall average annual cost per person was 
£21,605 equating to a national cost of £195 million per year.
Comment. This study identifies the high cost of informal 
care in HD which rises rapidly from stage III to IV. This may 
reflect the lack of effectiveness of outpatient-based care for 
these patients with higher levels of disability and the neces-
sity to instigate more comprehensive community care. A 
detailed understanding of the overall economic burden of 
disease in HD will be crucial in future cost utility analy-
sis of potential DMTs in HD. This study represents a good 
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first step in developing data for these purposes as well as 
directing and planning health care for this vulnerable group 
of patients but will need to be considerably more detailed 
and include additional data on domains such as work and 
employment in order that the true costs of HD are not 
underestimated.
Jones C et al. (2016) Eur J Neurol 23:1588–1590.
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